{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T01:00:34Z","timestamp":1785546034046,"version":"3.56.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":1136,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T00:00:00Z","timestamp":1664755200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015731","name":"Bayer Yakuhin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002336","name":"Daiichi Sankyo Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012351","name":"Mitsubishi Tanabe Pharma Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012351","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007132","name":"Otsuka Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Kochi Prefecture Sponsorship Project"},{"DOI":"10.13039\/100015731","name":"Bayer Yakuhin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002336","name":"Daiichi Sankyo Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012351","name":"Mitsubishi Tanabe Pharma Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012351","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007132","name":"Otsuka Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Guideline-directed medical therapy (GDMT) in patients with heart failure with reduced ejection fraction (HFrEF) is recommended in clinical guidelines, but elderly patients have not fully received GDMT in the clinical situation. The aim of this study was to determine the clinical characteristics of patients who have not received GDMT and the association between implementation of GDMT at discharge and physical frailty in patients with HFrEF who were hospitalized for acute decompensated heart failure (ADHF).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>This study was a cross-sectional study with a retrospective analysis of the Kochi YOSACOI study, a prospective multicentre observational study that enrolled 1061 patients hospitalized for ADHF from May 2017 to December 2019 in Japan. Of 339 patients (32.0%) with HFrEF, 268 patients who were assessed for physical frailty by the Japanese version of the Cardiovascular Health Study criteria were divided into two groups: those with GDMT (135 patients, 50.4%) and those without GDMT (133 patients, 49.6%). GDMT was defined as the prescription of a combination of renin-angiotensin system (RAS) inhibitors (angiotensin-converting inhibitors or angiotensin receptor blockers) and beta-blockers. The median age of patients with HFrEF was 76 years (interquartile range, 67\u201383 years). Patients without GDMT were older than patients with GDMT (73 years vs. 78 years, P &amp;lt; 0.001). Patients without GDMT tended to have more prior HF admission than did patients with GDMT (P = 0.004), and patients without GDMT had lower levels of estimated glomerular filtration rate (P &amp;lt; 0.001) than those in patients with GDMT. Physical frailty was observed in 54.1% of the patients without GDMT and in 38.5% of the patients with GDMT (P = 0.014). Patients without GDMT had a higher rate of cognitive impairment than that in patients with GDMT (P = 0.009). RAS inhibitors only, beta-blockers only, and both RAS inhibitors and beta-blockers were less frequently prescribed in patients with physical frailty than in patients with physical non-frailty (52.0% vs. 86.7%, P &amp;lt; 0.05; 70.1% vs. 100.0%, P &amp;lt; 0.05; 42.5% vs. 86.7%, P &amp;lt; 0.01, respectively). In logistic regression analysis, compared with physical non-frailty, physical frailty was significantly associated with no implementation of GDMT (odds ratio: 6.900, 95% confidence interval: 1.420\u201333.600; P = 0.017), independent of older age and severe renal dysfunction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The results of this study suggest that physical frailty is one of the factors that may withhold GDMT in patients with HFrEF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.14163","type":"journal-article","created":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T02:40:46Z","timestamp":1664851246000},"page":"223-233","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Frailty Interferes with the Guideline-Directed Medical Therapy in Heart Failure Patients with Reduced Ejection Fraction"],"prefix":"10.1093","volume":"10","author":[{"given":"Tomoyuki","family":"Hamada","sequence":"first","affiliation":[{"name":"Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University , Oko-cho, Nankoku-shi, Kochi, 783-8505 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Kubo","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University , Oko-cho, Nankoku-shi, Kochi, 783-8505 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Kawai","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Chikamori Hospital , Kochi ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Nakaoka","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Chikamori Hospital , Kochi ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshikazu","family":"Yabe","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kochi Prefectural Hatakenmin Hospital , Sukumo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Furuno","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kochi Prefectural Aki General Hospital , Aki ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisuke","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Susaki Kuroshio Hospital , Susaki ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Kitaoka","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University , Oko-cho, Nankoku-shi, Kochi, 783-8505 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Kochi YOSACOI study","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,10,3]]},"reference":[{"key":"2026012114122616900_ehf214163-bib-0001","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1056\/NEJMe020115","article-title":"Heart failure\u2014an epidemic of uncertain proportions","volume":"347","author":"Redfield","year":"2002","journal-title":"N Engl J Med"},{"key":"2026012114122616900_ehf214163-bib-0002","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1161\/CIR.0000000000000485","article-title":"Heart disease and strokes statistics\u20142017 update: a report from the American Heart Association","volume":"135","author":"Benjamin","year":"2017","journal-title":"Circulation"},{"key":"2026012114122616900_ehf214163-bib-0003","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1253\/circj.72.489","article-title":"Impending epidemic: future projection of heart failure in Japan to the year 2055","volume":"72","author":"Okura","year":"2008","journal-title":"Circ J"},{"key":"2026012114122616900_ehf214163-bib-0004","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/ejhf.319","article-title":"Heart failure as a general pandemic in Asia","volume":"17","author":"Shimokawa","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2026012114122616900_ehf214163-bib-0005","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/eurheartj\/ehn539","article-title":"Contemporary management of octogenarians hospitalized for heart failure in Europe: Euro Heart Failure Survey II","volume":"30","author":"Komajda","year":"2009","journal-title":"Eur Heart J"},{"key":"2026012114122616900_ehf214163-bib-0006","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1253\/circj.CJ-11-0267","article-title":"Predictors of long-term adverse outcomes in elderly patients over 80 years hospitalized with heart failure\u2014a report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD)","volume":"75","author":"Hamaguchi","year":"2011","journal-title":"Circ J."},{"key":"2026012114122616900_ehf214163-bib-0007","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/ejhf.518","article-title":"Prevalence and prognostic impact of frailty and its components in non-dependent elderly patients with heart failure","volume":"18","author":"Vid\u00e1n","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026012114122616900_ehf214163-bib-0008","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"2021","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2026012114122616900_ehf214163-bib-0009","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026012114122616900_ehf214163-bib-0010","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enarapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl Med"},{"key":"2026012114122616900_ehf214163-bib-0011","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012114122616900_ehf214163-bib-0012","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2026012114122616900_ehf214163-bib-0013","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.cardfail.2021.04.023","article-title":"JCS\/JHFS 2021 guideline focused update on diagnosis and treatment of acute and chronic heart failure","volume":"27","author":"Tsutsui","year":"2021","journal-title":"J Card Fail"},{"key":"2026012114122616900_ehf214163-bib-0014","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1001\/archinternmed.2011.31","article-title":"The persistent exclusion of older patients from ongoing clinical trials regarding heart failure","volume":"171","author":"Cherubini","year":"2011","journal-title":"Arch Intern Med"},{"key":"2026012114122616900_ehf214163-bib-0015","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/ejhf.1615","article-title":"Association between beta-blocker use and mortality\/morbidity in older patients with heart failure with reduced ejection fraction. A propensity score-matched analysis from the Swedish Heart Failure Registry","volume":"22","author":"Stolfo","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114122616900_ehf214163-bib-0016","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1093\/eurheartj\/ehy621","article-title":"Association between renin-angiotensin system inhibitor use and mortality\/morbidity in elderly patients with heart failure with reduced ejection fraction: a prospective propensity score-matched cohort study","volume":"39","author":"Savarese","year":"2018","journal-title":"Eur Heart J"},{"key":"2026012114122616900_ehf214163-bib-0017","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/ejhf.2206","article-title":"Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology","volume":"23","author":"Rosano","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114122616900_ehf214163-bib-0018","doi-asserted-by":"crossref","first-page":"M146","DOI":"10.1093\/gerona\/56.3.M146","article-title":"Frailty in older adults: evidence for a phenotype","volume":"56A","author":"Fried","year":"2001","journal-title":"J Gerontol A Biol Sci Med Sc"},{"key":"2026012114122616900_ehf214163-bib-0019","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1002\/ehf2.13363","article-title":"Frailty in patients with acute decompensated heart failure in a super-aged regional Japanese cohort","volume":"8","author":"Hamada","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026012114122616900_ehf214163-bib-0020","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1253\/circj.CJ-12-1091","article-title":"Geriatric nutritional risk index predicts functional dependency and mortality in patients with heart failure with preserved ejection fraction","volume":"77","author":"Kinugasa","year":"2013","journal-title":"Circ J"},{"key":"2026012114122616900_ehf214163-bib-0021","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1111\/ggi.13129","article-title":"Prevalence of frailty among community-dwellers and outpatients in Japan as defined by the Japanese version of the Cardiovascular Health Study criteria","volume":"17","author":"Satake","year":"2017","journal-title":"Geriatr Gerontol Int"},{"key":"2026012114122616900_ehf214163-bib-0022","first-page":"1339","article-title":"Preparation of revised Hasegawa's Dementia Scale (HDS-R)","volume":"2","author":"Kato","year":"1991","journal-title":"Jpn J Geriatr Psychiatr"},{"key":"2026012114122616900_ehf214163-bib-0023","first-page":"20","article-title":"The revised Hasegawa's Dementia Scale (HDS-R)\u2014evaluation of its usefulness as a screening test for dementia","volume":"4","author":"Imai","year":"1994","journal-title":"J Hong Kong Coll Psychiatr"},{"key":"2026012114122616900_ehf214163-bib-0024","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jchf.2020.08.017","article-title":"Heart failure hospitalization and guideline-directed prescribing patterns among heart failure with reduced ejection fraction patients","volume":"9","author":"Srivastava","year":"2021","journal-title":"JACC Heart Fail"},{"key":"2026012114122616900_ehf214163-bib-0025","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","article-title":"Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry","volume":"72","author":"Greene","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026012114122616900_ehf214163-bib-0026","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.008789","article-title":"Reasons for guideline nonadherence at heart failure discharge","volume":"7","author":"Gilstrap","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2026012114122616900_ehf214163-bib-0027","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.jcma.2017.04.011","article-title":"Gap between guidelines and clinical practice in heart failure with reduced ejection fraction: results from TSOC-HFrEF registry","volume":"80","author":"Chang","year":"2017","journal-title":"J Chin Med Assoc"},{"key":"2026012114122616900_ehf214163-bib-0028","first-page":"657","article-title":"Adherence to the guidelines on the management of systolic heart failure in ambulatory care in Poland. Data from the international QUALIFY survey","volume":"127","author":"Opolski","year":"2017","journal-title":"Pol Arch Intern Med"},{"key":"2026012114122616900_ehf214163-bib-0029","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ijcard.2017.02.070","article-title":"Current use of guideline-based medical therapy in elderly patients admitted with acute heart failure with reduced ejection fraction and its impact on event-free survival","volume":"235","author":"Akita","year":"2017","journal-title":"Int J Cardiol"},{"key":"2026012114122616900_ehf214163-bib-0030","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-030514","article-title":"Guideline-directed medical therapy in elderly patients with heart failure with reduced ejection fraction: a cohort study","volume":"10","author":"Seo","year":"2020","journal-title":"BMJ Open"},{"key":"2026012114122616900_ehf214163-bib-0031","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1253\/circrep.CR-20-0123","article-title":"Association between physical status and the effects of combination therapy with renin-angiotensin system inhibitors and \u03b2-blockers in patients with acute heart failure","volume":"3","author":"Takabayashi","year":"2021","journal-title":"Circ Rep"},{"key":"2026012114122616900_ehf214163-bib-0032","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.archger.2016.10.007","article-title":"Frailty and chronic kidney disease: a systematic review","volume":"68","author":"Chowdhury","year":"2017","journal-title":"Arch Gerontol Geriatr"},{"key":"2026012114122616900_ehf214163-bib-0033","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.jacc.2020.11.022","article-title":"2021 update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"77","author":"Writing Committee","year":"2021","journal-title":"J Am Coll Cardiol"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.14163","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.14163","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/10\/1\/223\/65108040\/eschf_10_1_223.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/10\/1\/223\/65108040\/eschf_10_1_223.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:14:02Z","timestamp":1769022842000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/10\/1\/223\/8304970"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,3]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,10,3]]},"published-print":{"date-parts":[[2023,2,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.14163","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,2]]},"published":{"date-parts":[[2022,10,3]]},"assertion":[{"value":"2022-05-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}